David P. Rosenbaum - Concepedia

Author

David P. Rosenbaum

Also Known As

D Rosenbaum, D Triezenberg, D. ROSENBAUM, D. Rosenbaum, David P Rosenbaum, David P. Rosenbaum, David Rosenbaum, Paul Korner, Rosenbaum D

117

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Ardelyx (United States)AstraZeneca (Sweden)Stanford University Michigan Medicine Colorado Kidney Care

About

David P. Rosenbaum is an author at Ardelyx (United States) specializing in medicine, health sciences, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	142
2	Health Sciences	2	2	44
3	Engineering	1	1	51
4	Public Health	1	1	20
5	Social Sciences	1	1	62

David P. Rosenbaum

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Intradialytic Hypotension and Risk of Cardiovascular Disease Bergur V. Stefánsson, Steven M. Brunelli, Claudia Cabrera, Clinical Journal of the American Society of Nephrology	2014	316
The Changing Landscape for Stroke Prevention in AF Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Journal of the American College of Cardiology	2017	276
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability Andrew J. King, Matthew Siegel, Ying He, Science Translational Medicine	2018	151
Intestinal Inhibition of the Na <sup>+</sup> /H <sup>+</sup> Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na <sup>+</sup> Uptake in Humans Andrew Spencer, Eric D. Labonté, David P. Rosenbaum, Science Translational Medicine	2014	146
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial Geoffrey A. Block, David P. Rosenbaum, Andrew T. Yan, Journal of the American Society of Nephrology	2019	113
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial William D. Chey, Anthony Lembo, David P. Rosenbaum The American Journal of Gastroenterology	2017	99
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis Geoffrey A. Block, David P. Rosenbaum, Maria Leonsson‐Zachrisson, Journal of the American Society of Nephrology	2017	97
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) William D. Chey, Anthony Lembo, David P. Rosenbaum The American Journal of Gastroenterology	2020	96
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY) Pablo E. Pérgola, David P. Rosenbaum, Yang� Yang, Journal of the American Society of Nephrology	2021	85
Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected Men Walter T. Hughes, Wren Kennedy, Jerry L. Shenep, The Journal of Infectious Diseases	1991	74

Page 1